LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 69

Search options

  1. Article ; Online: Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.

    Pearlman, Brian L

    Digestive diseases and sciences

    2024  

    Abstract: Patients with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis are an important population for antiviral therapy yet under-represented in clinical trials. HCV direct-acting antiviral (DAA) therapies, unlike interferon-containing ... ...

    Abstract Patients with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis are an important population for antiviral therapy yet under-represented in clinical trials. HCV direct-acting antiviral (DAA) therapies, unlike interferon-containing regimens, can be safely utilized in decompensated patients. Per guidelines from the American Association for the Study of Liver Diseases (AASLD), therapy of choice in HCV and decompensated cirrhosis is sofosbuvir, an HCV polymerase inhibitor, combined with a replication complex inhibitor (NS5A inhibitor) with or without ribavirin. Combination therapy with a HCV protease inhibitor and an NS5A inhibitor is effective in this population but is specifically not recommended in AASLD guidelines due to safety concerns. Important risk factors for further decompensation during DAA therapy are serum albumin < 3.5 g/dL, MELD (Model for End-Stage Liver Disease) score > 14, or HCV genotype 3 infection. Although sustained virologic response (SVR) is achieved less often in patients with decompensated vs compensated cirrhosis, in clinical studies response rates are > 80%. Both Child-Turcotte-Pugh Class at baseline and viral genotype can affect these response rates. Achieving SVR lowers risk of mortality, but to a lesser extent than in individuals with compensated cirrhosis. Likewise, treating patients for HCV infection along with successful treatment for hepatocellular carcinoma improves risks of both liver-related and overall mortality. In fewer than one third of cases, treating transplant-eligible, HCV-infected patients pre-transplant enables their delisting from transplant wait lists.
    Language English
    Publishing date 2024-04-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-024-08393-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui V Zs.35: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: A Patient With Jaundice and Malaise.

    Pearlman, Brian L

    JAMA

    2022  Volume 327, Issue 24, Page(s) 2448–2449

    MeSH term(s) Humans ; Jaundice/etiology
    Language English
    Publishing date 2022-06-13
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2022.8384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.88: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Challenging cases in the management of hepatitis C viral infection

    Pearlman, Brian L.

    a case study compendium

    (Gastroenterology & hepatology ; 5,4, Suppl. 11)

    2009  

    Author's details faculty Brian Pearlman
    Series title Gastroenterology & hepatology ; 5,4, Suppl. 11
    Collection
    Language English
    Size 14 S. : Ill.
    Publisher Gastro-Hep Comm
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT015936000
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6543 -5,Suppl.11- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?

    Pearlman, Brian L

    Annals of internal medicine

    2019  Volume 171, Issue 11, Page(s) 861–862

    MeSH term(s) Humans ; Israel ; Liver ; Non-alcoholic Fatty Liver Disease ; Teaching Rounds
    Language English
    Publishing date 2019-12-02
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/L19-0667
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.178/2: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Book: Treatment options for HCV nonresponders and relapse patients

    Pearlman, Brian L. / Sjogren, Maria H.

    (Gastroenterology & hepatology ; 6,3, Suppl. 6 : Clinical roundtable monograph)

    2010  

    Author's details faculty Brian L. Pearlman ; Maria H. Sjogren
    Series title Gastroenterology & hepatology ; 6,3, Suppl. 6 : Clinical roundtable monograph
    Collection
    Language English
    Size 10 S. : graph. Darst.
    Publisher Gastro-Hep Communications
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT016677437
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6543 --6,Suppl.6- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.

    Pearlman, Brian L / Hinds, Andrew E

    Alimentary pharmacology & therapeutics

    2018  Volume 48, Issue 9, Page(s) 914–923

    Abstract: Background: In 2017, the hepatitis C treatment regimens sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) and glecaprevir/pibrentasvir (G/P) received approval from the U.S. Food and Drug Administration. Although both SOF/VEL/VOX (NS5B polymerase ... ...

    Abstract Background: In 2017, the hepatitis C treatment regimens sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) and glecaprevir/pibrentasvir (G/P) received approval from the U.S. Food and Drug Administration. Although both SOF/VEL/VOX (NS5B polymerase inhibitor/NS5A inhibitor/NS3/4A protease inhibitor) and G/P (NS3/4A protease inhibitor/NS5A inhibitor) are pangenotypic regimens, they are indicated for distinct subsets of patients with hepatitis C.
    Aim: To compare and contrast available safety and efficacy data for SOF/VEL/VOX and G/P and outline their clinical utility.
    Methods: For each of the regimens, this review outlines the indications, safety information, and the major clinical studies in which SOF/VEL/VOX and G/P were evaluated.
    Results: SOF/VEL/VOX is positioned as a salvage regimen for patients previously treated with NS5A inhibitors and for genotype 1a- and 3-infected patients who had failed other sofosbuvir-containing regimens. G/P is the first pangenotypic regimen with an 8-week duration for treatment-naïve, non-cirrhotic patients, and it is indicated for patients with any genotype who have advanced kidney disease, including those on dialysis.
    Conclusion: The addition of SOF/VEL/VOX and G/P to existing hepatitis C treatment options will expand the number of patients who are eligible for and responsive to treatment, thus increasing the possibility of eliminating hepatitis C as a public health issue.
    MeSH term(s) Antiviral Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Carbamates/therapeutic use ; Clinical Trials, Phase III as Topic/methods ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/epidemiology ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; Macrocyclic Compounds/therapeutic use ; Quinoxalines/therapeutic use ; Sofosbuvir/therapeutic use ; Sulfonamides/therapeutic use
    Chemical Substances Antiviral Agents ; Benzimidazoles ; Carbamates ; Heterocyclic Compounds, 4 or More Rings ; Macrocyclic Compounds ; Quinoxalines ; Sulfonamides ; voxilaprevir (0570F37359) ; pibrentasvir (2WU922TK3L) ; glecaprevir (K6BUU8J72P) ; velpatasvir (KCU0C7RS7Z) ; Sofosbuvir (WJ6CA3ZU8B)
    Language English
    Publishing date 2018-10-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.14977
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2206: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

    Pearlman, Brian L

    The Lancet. Infectious diseases

    2012  Volume 12, Issue 9, Page(s) 717–728

    Abstract: For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin. With US Food and Drug Administration approval of boceprevir and telaprevir--two protease inhibitors--the standard-of-care ... ...

    Abstract For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin. With US Food and Drug Administration approval of boceprevir and telaprevir--two protease inhibitors--the standard-of-care treatment for genotype-1 infection, the main genotype worldwide, is now peginterferon plus ribavirin and a protease inhibitor. Rates of sustained virological response or cure with triple combination treatment have improved substantially, both in patients who have had previous treatment and in those who have not. Improvements have been most substantial in populations regarded as difficult to treat, such as individuals with cirrhosis. However, despite improved response rates, protease inhibitors have incremental toxic effects, high costs, increased pill burden, and many drug interactions. Moreover, because new antiviral drugs directly inhibit hepatitis C virus, viral resistance has become an important issue, essentially precluding use of protease inhibitor monotherapy, and potentially restricting future treatment options for patients who consequently do not achieve sustained virological response. Protease inhibitors are the first of many antiviral medications that will probably be combined in future interferon-free regimens.
    MeSH term(s) Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Drug Resistance, Viral ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Genotype ; Hepacivirus/classification ; Hepacivirus/genetics ; Hepacivirus/isolation & purification ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans ; Interferon-alpha/administration & dosage ; Oligopeptides/administration & dosage ; Oligopeptides/adverse effects ; Polyethylene Glycols/administration & dosage ; Proline/administration & dosage ; Proline/adverse effects ; Proline/analogs & derivatives ; Protease Inhibitors/administration & dosage ; Protease Inhibitors/adverse effects ; Recombinant Proteins/administration & dosage ; Ribavirin/administration & dosage ; Standard of Care/trends ; United States
    Chemical Substances Antiviral Agents ; Interferon-alpha ; Oligopeptides ; Protease Inhibitors ; Recombinant Proteins ; Polyethylene Glycols (30IQX730WE) ; Ribavirin (49717AWG6K) ; telaprevir (655M5O3W0U) ; N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (89BT58KELH) ; Proline (9DLQ4CIU6V) ; peginterferon alfa-2a (Q46947FE7K)
    Language English
    Publishing date 2012-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(12)70060-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5743: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Metabolic effects of tumescent liposuction.

    Ahmed, Areeba / Kyllo, Rachel L / Koza, Eric / Haq, Misha / Shi, Victoria J / Ma, Melissa / Weil, Alexandra / Wan, Hoi Ting / Poon, Emily / Pearlman, Ross / Schlessinger, Daniel I / Cahn, Brian A / Alam, Murad

    Archives of dermatological research

    2023  Volume 316, Issue 1, Page(s) 59

    MeSH term(s) Humans ; Lipectomy/adverse effects ; Lidocaine ; Anesthesia, Local
    Chemical Substances Lidocaine (98PI200987)
    Language English
    Publishing date 2023-12-27
    Publishing country Germany
    Document type Letter
    ZDB-ID 130131-7
    ISSN 1432-069X ; 0340-3696
    ISSN (online) 1432-069X
    ISSN 0340-3696
    DOI 10.1007/s00403-023-02809-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187-192.

    Pearlman, Brian L / Hinds, Andrew / Dakaud, Alexandra-Elise Zakaud

    Diabetes care

    2018  Volume 41, Issue 9, Page(s) e136

    MeSH term(s) African Americans ; Alanine Transaminase ; Humans ; Non-alcoholic Fatty Liver Disease
    Chemical Substances Alanine Transaminase (EC 2.6.1.2)
    Language English
    Publishing date 2018-08-15
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 441231-x
    ISSN 1935-5548 ; 0149-5992
    ISSN (online) 1935-5548
    ISSN 0149-5992
    DOI 10.2337/dc18-0946
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1434: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 365: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.

    Pearlman, Brian L

    Current gastroenterology reports

    2010  Volume 13, Issue 1, Page(s) 78–86

    Abstract: The hypothesis that host genetics play an essential role in the ability not only to clear acute hepatitis C infection but also to achieve sustained virologic response (SVR) to interferon (IFN)-based therapy has been proved with the recent discovery of ... ...

    Abstract The hypothesis that host genetics play an essential role in the ability not only to clear acute hepatitis C infection but also to achieve sustained virologic response (SVR) to interferon (IFN)-based therapy has been proved with the recent discovery of two single-nucleotide polymorphisms on chromosome 19. Variants in the minor allele rs8099917 and the proximate polymorphism rs12979860, 3 kb upstream of the interleukin (IL)-28B gene, which encodes the endogenous antiviral cytokine IFN-λ, are associated with SVR and with natural viral clearance. The disparate frequencies of these alleles in ethnic groups worldwide may well explain differing rates of SVR among them. The test for one of these polymorphisms is now commercially available and can serve as a powerful predictor of a patient's chance of achieving SVR. Perhaps more importantly, the test can help the clinician personally tailor the duration and even the type of therapy that is most appropriate for an individual patient, newly or chronically infected with the hepatitis C virus.
    MeSH term(s) Antiviral Agents/therapeutic use ; Genetic Testing ; Genome-Wide Association Study ; Genotype ; Hepacivirus/isolation & purification ; Hepatitis C/drug therapy ; Hepatitis C/ethnology ; Hepatitis C/immunology ; Hepatitis C/virology ; Humans ; Interferons/therapeutic use ; Interleukins/genetics ; Interleukins/immunology ; Polymorphism, Single Nucleotide ; Viral Load
    Chemical Substances Antiviral Agents ; interferon-lambda, human ; Interleukins ; Interferons (9008-11-1)
    Language English
    Publishing date 2010-11-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2041376-2
    ISSN 1534-312X ; 1522-8037
    ISSN (online) 1534-312X
    ISSN 1522-8037
    DOI 10.1007/s11894-010-0161-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5751: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top